ArticlePloS one2026
Breast cancer clustering integrating complete gene expression profiles and genetic ancestry.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) remains the leading cause of cancer-related mortality among women globally. Precise subtyping of BC is critical for optimizing treatment strategies. This study explored the capacity of bulk RNA-seq data to improve breast cancer characterization by analysis of complete expression profiles. We analyzed RNA-seq data for 274 tumor samples and six healthy tissue samples from diverse geographical origins. Using over 9,800 SNPs directly genotyped from RNA-seq data, we successfully predicted broad genetic ancestry, identifying European, African, Asian, South Asian, and Admixed American origins. Molecular subtyping through PAM50 showed some level of ambiguity, depending on the amount of samples provided as input. In silico drug sensitivity analysis identified potential therapeutic strategies, including Etoposide and Mistaurin, with cluster-specific efficacy. Our findings emphasize the integration of ancestry-informed data and complete transcriptomic profiles to redefine BC subtyping. These insights offer a foundation for more equitable, ancestry-informed therapeutic strategies and highlight the importance of diversity in cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.